Contributor Since 2017
Kidney Cancer Drugs/Renal Cell Carcinoma (RCC) Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025, the global kidney cancer/ renal cell carcinoma drugs market was valued at US$ 3,302.3 Mn in 2016, and is expected to reach US$ 6,441.9 Mn by 2025, expanding at a CAGR of 8.1% from 2017 to 2025.
Browse Full Report Visit :- Global Kidney Cancer Drugs/Renal Cell Carcinoma (RCC) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025 | Acute Market Reports
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women. According to American Cancer Society study in U.S. around 63,990 adults (40,610 men and 23,380 women) new cases of kidney cancer will be diagnosed. The average age of diagnosis is 64 and is rarely found in people under 45. It is estimated that 65% of people are diagnosed when the cancer is only located in the kidney and the 5-year survival rate is 93% in this group. The incidence of renal cell cancer is observed highest in Northern America and Europe. Almost 59%of kidney cancer cases is observed in developed countries. Thus, rising incidence of kidney cancer and entry of novel drug treatment are the key factors contributing to the growth of kidney cancer drug market.
The global kidney cancer drugs market is segmented by drugs type into Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus) and Proleukin (Aldesleukin). Sutent dominates the global kidney cancer/renal cell carcinoma drugs market.
As of the current market scenario, North America dominates the global kidney cancer drugs market followed by the Europe. Rise in incidence of renal cancer, increasing geriatric population and novel drug treatment are key drivers for the growth of kidney cancer drug market in North America. Asia Pacific is the fastest growing regional market for kidney cancer drugs with highest CAGR in the forecast period. With improvement in diagnostic technology, rise in aged population and low cost production of drugs are some of the key factors contributing to the growth of Asia Pacific region.
Market Competition Assessment:
Key players in the global kidney cancer drugs market are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ag, Genentech, Inc., Glaxosmithkline Plc, Novartis AG, Onyx, Pfizer, Inc. and others.
Download Free Sample Request :- Request Sample | Acute Market Reports
Key Market Movements:
• Kidney cancer is the most common cancer observed falling within top ten most common cancer in both male and female. Rising incidence of kidney cancer due to adoption of unhealthy life style such as smoking, drinking and less physical activity. Thus increase in aged population and incidence of kidney cancer would propel the growth of kidney cancer drugs market.
• Further approval of novel drugs would fuel the growth of global kidney cancer drugs market
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Kidney Cancer Drugs Market Portraiture
2.1.1. Global Kidney Cancer Drugs Market, by Drug Type, 2016
2.1.2. Global Kidney Cancer Drugs Market, by Geography, 2016
Chapter 3. Kidney Cancer Drugs: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Epidemiology of Kidney Cancer
3.5.1. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016
To Get Complete Report @ Global Kidney Cancer Drugs/Renal Cell Carcinoma (RCC) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025 | Acute Market Reports
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the worlds most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us :
Name : Chris Paul
ACUTE MARKET REPORTS
Designation : Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email : firstname.lastname@example.org
Website : http://www.acutemarketreports.com